Cargando…
Loading, please waitCargando…
Loading, please waitCondition Focus — MS
A clear, conservative explanation of where mesenchymal stem cell (MSC) therapy stands for multiple sclerosis in 2026 — at Regeneris Therapy, a COFEPRIS-regulated regenerative-medicine clinic in Cancún, México. What the evidence actually shows, why MSC therapy is not the same as aHSCT, who may be a candidate, and how an honest evaluation works.
Clinical overview
Multiple sclerosis is a chronic, immune-mediated disease of the central nervous system in which the immune system attacks the myelin sheath that insulates nerve fibers, disrupting the electrical signals that travel along them. Over time the inflammatory injury can damage the underlying axons themselves, producing the accumulating disability seen in some forms of the disease. Standard of care is a disease-modifying therapy (DMT) prescribed by a neurologist; the field of regenerative medicine sits alongside that standard, not in place of it.
MSC therapy is studied as an adjunct that may modulate the inflammatory environment in MS — not as a stand-alone substitute for the DMT your neurologist has prescribed. Any conversation about it in Cancún, México starts from that premise.
What the evidence shows
An honest summary of the published evidence for mesenchymal stem cell therapy in MS. The signal is mixed: safety has been consistent across small trials, but the largest randomized study to date did not show a clear benefit on its primary imaging endpoint. None of this guarantees an individual outcome, and a Regeneris physician matches the modality to the strength of evidence for your specific case in Cancún, México.
The field's own founder reframed these cells as "medicinal signaling cells," arguing that their benefit comes chiefly from secreted, paracrine factors (exosomes, cytokines, growth factors) that modulate inflammation rather than from engraftment and tissue replacement. This is the mechanistic basis on which MSC protocols for autoimmune-adjacent conditions are studied.
A randomized, double-blind, placebo-controlled, crossover Phase II trial of autologous bone-marrow MSCs in relapsing-remitting MS reported that the therapy was safe and may reduce inflammatory MRI parameters, supporting an immunomodulatory effect — while emphasizing that confirmatory studies were required before drawing efficacy conclusions.
The MESEMS trial — a multicenter, randomized, double-blind, crossover Phase 2 study at 15 sites in nine countries — tested intravenous autologous bone-marrow MSCs versus placebo in 144 patients with active MS. MSC infusion was safe and well tolerated, but the primary endpoint (number of gadolinium-enhancing brain lesions at 24 weeks) did not differ from placebo. This is the most rigorous trial to date and the result is honestly mixed.
An academic pilot trial of intravenous, autologous, culture-expanded MSC transplantation in MS patients reported the procedure as feasible and safe, with exploratory measures of disease activity collected as hypothesis-generating data. Like other early studies, it informs design and dosing rather than establishing efficacy.
The International MSCT Study Group — a panel of MS neurologists, stem-cell experts, and immunologists — published a consensus report on the rationale, protocols, and methodologic standards for studying MSC transplantation in MS, framing it as a promising investigational approach that should be developed under rigorous trial conditions.
The honest takeaway: MSC therapy for MS shows a consistent safety profile and a biologically plausible mechanism, but efficacy on hard imaging endpoints has not been established in the largest randomized trial. We will not promise a benefit we cannot deliver — and we will tell you that during your evaluation in Cancún, México.
Important distinction
Two procedures often get blurred together in online discussions of "stem cells for MS." They are very different in design, risk, and what they aim to do. Regeneris Therapy in Cancún, México performs the first — mesenchymal stem cell (MSC) therapy. We do not perform the second.
If a clinic markets a single "stem cell cure for MS" without making this distinction, that is a red flag. At Regeneris Therapy in Cancún, México the distinction is part of every conversation.
Honest candidacy
MSC therapy for MS is considered only as a careful adjunct, after coordinating with your neurologist. The bullets below are general orientation — not a substitute for an evaluation in Cancún, México.
Regulation & location
Regeneris Therapy is a regenerative-medicine clinic in Cancún, México, regulated by COFEPRIS — Mexico's federal health authority, equivalent in scope to the U.S. FDA. Operating in Cancún means three things at once: a federally regulated medical environment, a recognized international medical-tourism destination on the Mexican Caribbean with direct flights from across the U.S. and Canada, and a single coordinated team for evaluation, treatment, and follow-up.
Regeneris operates under Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 — registered medical activity under Mexican federal regulation, performed in Cancún, México.
Cells are sourced, processed, and stored through COFEPRIS-certified laboratory partners with documented sterility, viability, and identity testing for every batch — the same supply chain used across our stem-cell protocols in Cancún, México.
Every MS case is reviewed by a licensed physician in Cancún, México, and your neurologist's notes and most recent MRI are part of the conversation. Coordination, not replacement, is the rule.
How Regeneris works
Our model is simple and deliberate: a free medical evaluation first, a personalized written quote second, and a decision that is yours to make in your own time. We do not publish prices online for regenerative protocols and we do not bundle MS into an off-the-shelf package — every case is individualized in Cancún, México.
Send your diagnosis, current DMT and dose, recent MRI, and any neurology notes. A Regeneris physician in Cancún, México reviews your case and decides honestly whether MSC therapy is a reasonable adjunct, deferred, or not appropriate.
If MSC therapy is reasonable, your physician designs a plan that respects your existing neurology care — never replaces it — and explains realistic expectations, including that this is investigational for MS.
Only after the evaluation do you receive a personalized written quote with the proposed protocol, scope, and inclusions. There are no online prices because there is no standard package — your case dictates the plan.
If you proceed, your visit to Cancún, México is coordinated end-to-end — evaluation, infusion under medical supervision, and structured follow-up with your neurologist looped in for ongoing care.
Realistic expectations
Multiple sclerosis is a YMYL (your-money-or-your-life) topic and we treat it that way. We will not promise a cure, reversal of disability, or replacement of your DMT. We will explain what is known, what is not, and what an adjunct can reasonably aim for under conservative medical supervision in Cancún, México.
It is not an approved disease-modifying therapy. The largest randomized trial (MESEMS, 2021) did not meet its primary efficacy endpoint. Any individual response is uncertain.
MSC therapy at Regeneris is studied and discussed only as an adjunct to your neurologist-prescribed DMT — never as a reason to stop or pause it without your treating neurologist's decision.
We do not publish prices online and do not sell a single MS package. Every plan and quote is individualized after a free medical evaluation.
We do not perform autologous hematopoietic stem cell transplantation. If that is what your case calls for, we will say so and direct you to a qualified transplant center.
FAQ
The questions patients with multiple sclerosis most often ask us before traveling to Cancún, México for an evaluation.
No. There is no proven cure for multiple sclerosis, and stem cell therapy — whether mesenchymal stem cell (MSC) therapy or autologous hematopoietic stem cell transplantation (aHSCT) — is not an approved disease-modifying therapy. MSC therapy is investigational for MS; the largest randomized trial to date (MESEMS, Lancet Neurology 2021) found it safe but did not meet its primary efficacy endpoint at 24 weeks. At Regeneris Therapy in Cancún, México we offer MSC therapy only as a careful adjunct to a neurologist-prescribed DMT — never as a substitute and never as a cure.
No — they are very different procedures often confused online. MSC therapy is an intravenous infusion of mesenchymal stem cells whose effect is studied through paracrine, immunomodulatory signaling, performed in clinic with no chemotherapy and no hospital admission. Autologous hematopoietic stem cell transplantation (aHSCT) is an immunoablative procedure that uses high-dose chemotherapy to wipe out the immune system before rebuilding it from the patient's own blood-forming stem cells; it is performed only at specialized transplant centers. Regeneris in Cancún, México offers MSC therapy. We do not perform aHSCT, and if aHSCT is the right path for you we will say so honestly.
No — and any clinic that suggests so should be treated with extreme caution. Disease-modifying therapy is the standard of care for MS and is prescribed and monitored by your neurologist. MSC therapy at Regeneris Therapy in Cancún, México is discussed only as an adjunct, with your neurologist informed, and never as a reason to discontinue your DMT. Any change to your DMT is a decision for your treating neurologist, not a regenerative-medicine clinic.
In general terms, adults with a confirmed MS diagnosis who are stable on a neurologist-prescribed DMT, whose neurologist is informed of and supportive of an investigational adjunct, and who understand that MSC therapy is not a cure and not approved as a DMT. Patients with active untreated malignancy, uncontrolled infection, pregnancy or lactation, or who are seeking aHSCT are not candidates here. Final candidacy is always confirmed in a free medical evaluation in Cancún, México — not assumed from a symptom or diagnosis alone.
Because the mechanism is biologically plausible, the safety profile across trials has been consistent, and a careful, COFEPRIS-regulated, physician-supervised adjunct is meaningfully different from unmonitored experimentation. Regeneris operates in Cancún, México under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053, with a certified laboratory chain and neurology coordination. We treat MS only as an adjunct, with honest disclaimers — and the published evidence (Llufriu 2014; MESEMS 2021) is presented openly during your evaluation.
You start with a free medical evaluation — send your MS diagnosis, current DMT, most recent MRI, and any neurology notes through our contact form or WhatsApp. A Regeneris physician in Cancún, México reviews your case and either proposes a coordinated plan or honestly declines. We do not publish prices online for regenerative protocols and we do not sell an off-the-shelf MS package; any personalized written quote is issued only after the evaluation, so the figure you see reflects your specific case rather than a generic list.
Continue exploring
The full pillar on mesenchymal stem cell therapy at Regeneris in Cancún, México: cell sources, mechanism, protocols, and how to start.
ContinueHow COFEPRIS regulation, certified labs, and physician oversight make stem-cell care in Cancún different from unregulated tourism.
ContinueTravel, logistics, and what to bring from your neurologist when coming to Cancún, México from the U.S. or Canada.
ContinueA 2026 comparison of regulation, available cell types, and cross-border considerations for regenerative care.
ContinueSend your MS diagnosis, DMT, and most recent MRI to start a free medical evaluation in Cancún, México.
ContinueThis page is informational and does not constitute medical advice. Mesenchymal stem cell therapy is investigational for multiple sclerosis and is not an approved disease-modifying therapy; outcomes are uncertain and vary by patient, disease phenotype, and protocol. MSC therapy is not a cure for MS and is offered at Regeneris Therapy in Cancún, México only as an adjunct to neurologist-prescribed care, after a free medical evaluation. Regeneris does not perform autologous hematopoietic stem cell transplantation (aHSCT). Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 in Cancún, Quintana Roo, México.
Book a free 15-min call with our team.
Share your diagnosis, current DMT, recent MRI, and neurology notes. A physician in Cancún, México will review your case and tell you honestly whether an MSC adjunct is reasonable, deferred, or not appropriate — with a personalized written quote after your free medical evaluation.